Biology & biomedicineNew biomimetic skin gels patents, developed at IQAC-CSIC, are acquired by Bicosome
- Details
- Category: Success stories
-
13 Feb 2023
Two new patents developed at the Institute of Advanced Chemistry of Catalonia (IQAC) from the CSIC have been licensed by Bicosome company. The new technological platforms made of only lipids and water do not need the presence of polymers, surfactants, or other gelling agents, bringing valuable benefits for skin care, especially sensitive skin.
New project develops advanced biomaterials for complex wound healing
- Details
- Category: Projects
-
03 Feb 2023
The European project, Nabiheal, will work on the synthesis of advanced biomaterials as an alternative to silver-based dressings commonly used for wound healing. The new materials will be cheaper, safer and more sustainable.
Three epigenetic biomarkers of thyroid cancer identified to facilitate diagnosis
- Details
- Category: Technological offers
-
05 Dec 2022
A team from CSIC and the FINBA Foundation has identified three biomarkers that predict with high specificity and sensitivity the malignancy of a thyroid nodule, which could avoid many unnecessary surgeries. They are now looking for interested companies to develop specific kits.
Graphene-based biosensor enables ultra-sensitive detection of hepatitis C virus
- Details
- Category: Technological offers
-
29 Dec 2022
An international team with CSIC participation has successfully developed and validated a biosensor for the ultra-sensitive detection of the hepatitis C virus (HCV). The device is based on graphene transistors that can detect key proteins of the virus. The results of this research appear in the journal Biosensors and Bioelectronics and the scientific team has already applied for the international patent of the invention.
New drug composition for uveal melanoma developed
- Details
- Category: Technological offers
-
31 Oct 2022
CSIC has developed a pharmaceutical composition to treat uveal melanoma, a cancer that forms from melanin-producing cells in the eye. Although it has a low incidence, it is the most common eye cancer in adults. There are a few standard treatments for the primary tumour, but not for metastatic uveal melanoma of the eye.
